BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 29748444)

  • 41. Multicenter, Open-Label, Phase II Study of Bendamustine and Rituximab Followed by 90-Yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe).
    Lansigan F; Costa CA; Zaki BI; Yen SP; Winer ES; Ryan H; Findley D; Metzler SR; Shaw L; Toaso B; MacKenzie TA; Chen Y; Beaven AW
    Clin Cancer Res; 2019 Oct; 25(20):6073-6079. PubMed ID: 31243122
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi.
    Zaja F; Ferrero S; Stelitano C; Ferrari A; Salvi F; Arcari A; Musuraca G; Botto B; Spina M; Cellini C; Patti C; Liberati AM; Minotto C; Pileri SA; Ceccarelli M; Volpetti S; Ferranti A; Drandi D; Montechiarello E; Ladetto M; Carmichael J; Fanin R
    Haematologica; 2017 May; 102(5):e203-e206. PubMed ID: 28082342
    [No Abstract]   [Full Text] [Related]  

  • 43. Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings.
    Czuczman MS; Goy A; Lamonica D; Graf DA; Munteanu MC; van der Jagt RH
    Ann Hematol; 2015 Dec; 94(12):2025-32. PubMed ID: 26411584
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Front-line high-dose chemotherapy with rituximab showed excellent long-term survival in adults with aggressive large b-cell lymphoma: final results of a Phase II GOELAMS Study.
    Dilhuydy MS; Lamy T; Foussard C; Gressin R; Casassus P; Deconninck E; Le Maignan C; Damotte D; Milpied N;
    Biol Blood Marrow Transplant; 2010 May; 16(5):672-7. PubMed ID: 20045738
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials.
    Gentile M; Zirlik K; Ciolli S; Mauro FR; Di Renzo N; Mastrullo L; Angrilli F; Molica S; Tripepi G; Giordano A; Di Raimondo F; Selleri C; Coscia M; Musso M; Orsucci L; Mannina D; Rago A; Giannotta A; Ferrara F; Herishanu Y; Shvidel L; Tadmor T; Scortechini I; Ilariucci F; Murru R; Guarini A; Musuraca G; Mineo G; Vincelli I; Arcari A; Tarantini G; Caparrotti G; Chiarenza A; Levato L; Villa MR; De Paolis MR; Zinzani PL; Polliack A; Morabito F
    Eur J Cancer; 2016 Jun; 60():154-65. PubMed ID: 27127905
    [TBL] [Abstract][Full Text] [Related]  

  • 46. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
    Eichhorst B; Fink AM; Bahlo J; Busch R; Kovacs G; Maurer C; Lange E; Köppler H; Kiehl M; Sökler M; Schlag R; Vehling-Kaiser U; Köchling G; Plöger C; Gregor M; Plesner T; Trneny M; Fischer K; Döhner H; Kneba M; Wendtner CM; Klapper W; Kreuzer KA; Stilgenbauer S; Böttcher S; Hallek M; ;
    Lancet Oncol; 2016 Jul; 17(7):928-942. PubMed ID: 27216274
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Sehn LH; Herrera AF; Flowers CR; Kamdar MK; McMillan A; Hertzberg M; Assouline S; Kim TM; Kim WS; Ozcan M; Hirata J; Penuel E; Paulson JN; Cheng J; Ku G; Matasar MJ
    J Clin Oncol; 2020 Jan; 38(2):155-165. PubMed ID: 31693429
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bendamustin-Rituximab Combination Is a Safe and Effective, Ambulatory Treatment for Elderly Patients with Chronic Lymphocytic Leukemia: Retrospective Real-world Analysis by Age from a German Registry and Review of the Literature.
    Kleeberg UR; Linde H; Günther G; Tessen HW; Kersting M
    Anticancer Res; 2016 Jun; 36(6):2827-38. PubMed ID: 27272794
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Is bendamustine-rituximab a reasonable treatment in selected older patients with diffuse large B cell lymphoma? Results from a multicentre, retrospective study.
    Zeremski V; Jentsch-Ullrich K; Kahl C; Mohren M; Eberhardt J; Fischer T; Schalk E
    Ann Hematol; 2019 Dec; 98(12):2729-2737. PubMed ID: 31705183
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a retrospective analysis.
    Merchionne F; Quintana G; Gaudio F; Minoia C; Specchia G; Guarini A; Quarta G; Pavone V; Melpignano A
    Leuk Res; 2014 Dec; 38(12):1446-50. PubMed ID: 25455656
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.
    Hiddemann W; Barbui AM; Canales MA; Cannell PK; Collins GP; Dürig J; Forstpointner R; Herold M; Hertzberg M; Klanova M; Radford J; Seymour JF; Tobinai K; Trotman J; Burciu A; Fingerle-Rowson G; Wolbers M; Nielsen T; Marcus RE
    J Clin Oncol; 2018 Aug; 36(23):2395-2404. PubMed ID: 29856692
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial.
    Kambhampati S; Fakhri B; Ai WZ; Kaplan LD; Tuscano JM; Wieduwilt MJ; Sudhindra A; Cavallone E; Reiner J; Aoun C; Castillo M; Martinelli M; Ta T; Le D; Padilla M; Crawford E; Andreadis CB
    Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):139-146. PubMed ID: 33478921
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.
    Awan FT; Gore L; Gao L; Sharma J; Lager J; Costa LJ
    Br J Haematol; 2016 Oct; 175(1):55-65. PubMed ID: 27293194
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab.
    Cencini E; Sicuranza A; Fabbri A; Ferrigno I; Rigacci L; Cox MC; Raspadori D; Bocchia M
    Br J Haematol; 2019 Jan; 184(2):223-231. PubMed ID: 30203425
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Retrospective analysis of frontline treatment efficacy in elderly patients with diffuse large B-cell lymphoma.
    Cheng CL; Liu JH; Chou SC; Yao M; Tang JL; Tien HF
    Eur J Haematol; 2018 Jul; 101(1):28-37. PubMed ID: 29603428
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi.
    Merli F; Luminari S; Rossi G; Mammi C; Marcheselli L; Tucci A; Ilariucci F; Chiappella A; Musso M; Di Rocco A; Stelitano C; Alvarez I; Baldini L; Mazza P; Salvi F; Arcari A; Fragasso A; Gobbi PG; Liberati AM; Federico M
    Leuk Lymphoma; 2012 Apr; 53(4):581-8. PubMed ID: 21895543
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
    Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
    Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients.
    González-Barca E; Canales MA; Salar A; Ferrer S; Domingo-Domenech E; Vidal MJ; Grande C; Bargay J; Gardella S; Oriol A; Briones J; García-Frade J; Bello JL; Sánchez-Blanco JJ; Peñalver FJ; Tomás JF; Asensio A; López A; Caballero D;
    Acta Haematol; 2016; 136(2):76-84. PubMed ID: 27188649
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study.
    Michallet AS; Aktan M; Hiddemann W; Ilhan O; Johansson P; Laribi K; Meddeb B; Moreno C; Raposo J; Schuh A; Ünal A; Widenius T; Bernhardt A; Kellershohn K; Messeri D; Osborne S; Leblond V
    Haematologica; 2018 Apr; 103(4):698-706. PubMed ID: 29419437
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.
    Peyrade F; Jardin F; Thieblemont C; Thyss A; Emile JF; Castaigne S; Coiffier B; Haioun C; Bologna S; Fitoussi O; Lepeu G; Fruchart C; Bordessoule D; Blanc M; Delarue R; Janvier M; Salles B; André M; Fournier M; Gaulard P; Tilly H;
    Lancet Oncol; 2011 May; 12(5):460-8. PubMed ID: 21482186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.